Rosalind F. Roberts

Rosalind F. Roberts

Auto-generated profile, based on publicly available information

Rosalind F. Roberts

McGill Parkinson Program, Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2017 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
NBNora Bengoa-Vergniory
Nora Bengoa-Vergniory
RRRosalind F. Roberts
Rosalind F. Roberts
RWRichard Wade-Martins
Richard Wade-Martins
JAJavier Alegre Abarrategui
Javier Alegre Abarrategui
Alpha-synuclein is a protein implicated in Parkinson’s disease and thought to be one of the main pathological drivers in the disease, although it remains unclear how this protein elicits its neurotoxic effects. Recent findings indicate that the assembly of toxic oligomeric species of alpha-synuclein may be one of the key processes for the pathology and spread of the disease. The absence of a sensitive in situ detection method has hindered the study of these oligomeric species and the role they play in the human brain until recently. In this review, we assess the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discuss the advances in our understanding of the role of alpha-synuclein in Parkinson’s disease that may be brought about by the specific and sensitive detection of distinct oligomeric species in post-mortem patient brain. Finally, we discuss current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications.

1 March 2015 in Brain
Verified
Journal Article
Open access
PDF file
RRRosalind F. Roberts
Rosalind F. Roberts
RWRichard Wade-Martins
Richard Wade-Martins
JAJavier Alegre Abarrategui
Javier Alegre Abarrategui
Oligomeric forms of alpha-synuclein are emerging as key mediators of pathogenesis in Parkinson’s disease. Our understanding of the exact contribution of alpha-synuclein oligomers to disease is limited by the lack of a technique for their specific detection. We describe a novel method, the alpha-synuclein proximity ligation assay, which specifically recognizes alpha-synuclein oligomers. In a blinded study with post-mortem brain tissue from patients with Parkinson’s disease (n = 8, age range 73–92 years, four males and four females) and age- and sex-matched controls (n = 8), we show that the alpha-synuclein proximity ligation assay reveals previously unrecognized pathology in the form of extensive diffuse deposition of alpha-synuclein oligomers. These oligomers are often localized, in the absence of Lewy bodies, to neuroanatomical regions mildly affected in Parkinson’s disease. Diffuse alpha-synuclein proximity ligation assay signal is significantly more abundant in patients compared to controls in regions including the cingulate cortex (1.6-fold increase) and the reticular formation of the medulla (6.5-fold increase). In addition, the alpha-synuclein proximity ligation assay labels very early perikaryal aggregates in morphologically intact neurons that may precede the development of classical Parkinson’s disease lesions, such as pale bodies or Lewy bodies. Furthermore, the alpha-synuclein proximity ligation assay preferentially detects early-stage, loosely compacted lesions such as pale bodies in patient tissue, whereas Lewy bodies, considered heavily compacted late lesions are only very exceptionally stained. The alpha-synuclein proximity ligation assay preferentially labels alpha-synuclein oligomers produced in vitro compared to monomers and fibrils, while stained oligomers in human brain display a distinct intermediate proteinase K resistance, suggesting the detection of a conformer that is different from both physiological, presynaptic alpha-synuclein (proteinase K-sensitive) and highly aggregated alpha-synuclein within Lewy bodies (proteinase K-resistant). These disease-associated conformers represent previously undetected Parkinson’s disease pathology uncovered by the alpha-synuclein proximity ligation assay.

1 October 2016 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
RRRosalind F. Roberts
Rosalind F. Roberts
MTMatthew Y. Tang
Matthew Y. Tang
EFEdward A. Fon
Edward A. Fon
TDThomas M. Durcan
Thomas M. Durcan

20 April 2019 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
JAJavier Alegre Abarrategui
Javier Alegre Abarrategui
KBKatherine R. Brimblecombe
Katherine R. Brimblecombe
RRRosalind F. Roberts
Rosalind F. Roberts
EVElisavet Velentza-Almpani
Elisavet Velentza-Almpani
BTBension S. Tilley
Bension S. Tilley
CPChristos Proukakis
Christos Proukakis
Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy are neurodegenerative disorders resulting in progressive motor/cognitive deficits among other symptoms. They are characterised by stereotypical brain cell loss accompanied by the formation of proteinaceous aggregations of the protein α-synuclein (α-syn), being, therefore, termed α-synucleinopathies. Although the presence of α-syn inclusions is a common hallmark of these disorders, the exact nature of the deposited protein is specific to each disease. Different neuroanatomical regions and cellular populations manifest a differential vulnerability to the appearance of protein deposits, cell dysfunction, and cell death, leading to phenotypic diversity. The present review describes the multiple factors that contribute to the selective vulnerability in α-synucleinopathies. We explore the intrinsic cellular properties in the affected regions, including the physiological and pathophysiological roles of endogenous α-syn, the metabolic and genetic build-up of the cells and their connectivity. These factors converge with the variability of the α-syn conformational strains and their spreading capacity to dictate the phenotypic diversity and regional vulnerability of each disease. Finally, we describe the exogenous and environmental factors that potentially contribute by igniting and modulating the differential pathology in α-synucleinopathies. In conclusion, we think that it is the confluence of this disruption of the cellular metabolic state and α-syn structural equilibrium through the anatomical connectivity which appears to initiate cascades of pathological processes triggered by genetic, environmental, or stochastic events that result in the “death by a thousand cuts” profile of α-synucleinopathies.

2 September 2016 in Cell Research
Verified
Journal Article
Closed access
RRRosalind F Roberts
Rosalind F Roberts
EFEdward A. Fon
Edward A. Fon

26 November 2020 in Journal of Proteome Research
Verified
Journal Article
Closed access
RRRosalind F. Roberts
Rosalind F. Roberts
ABAndrew N. Bayne
Andrew N. Bayne
TGThomas Goiran
Thomas Goiran
DLDominique Lévesque
Dominique Lévesque
FBFrançois-Michel Boisvert
François-Michel Boisvert
EFEdward A. Fon
Edward A. Fon